ARCHIVES

FDA Committee Okays Carboplatin For Second Line Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 15 No. 01 | January 6, 1989

Download PDF Visit The Full Archive

Related Articles

Aggressive Cancer Screening Increases Overdiagnosis, JAMA Paper Argues

October 30, 2009

DePinho’s Wife Was Briefed on AVEO Data 11 Days Before He Touted Stock on CNBC

September 13, 2013

Phase II Study Of Pfizer Drug Meets Primary Endpoint

April 24, 2009

Trials show No Advantage for ABMT In Breast Cancer; Should Insurers Pay?

April 16, 1999

Harvest Yet To Come From Radiotherapy Advances, Kaplan Tells NCAB

October 17, 1975

FDA Approvals: Lymphoseek Label Updated to Include Head and Neck SCC

June 27, 2014